Cache Test Div
top new

Hervorragende Patientenergebnisse

Orsiro wurde 2011 ins Leben gerufen und verfügt über ein umfangreiches klinisches Programm mit mehr als 48.500 eingeschlossenen Patienten. Orsiro Mission verwendet das klinisch erprobte Orsiro DES für ein völlig neues Liefersystem.
View All Clinical Studies

BIOFLOW-V (n = 1,334) FDA pivotal trial

5-year results: Orsiro - pushing the boundaries of performance2,a

PRINCIPAL INVESTIGATOR OF THE FDA PIVOTAL BIOFLOW-V TRIAL PRESENTS 5-YEAR OUTCOMES2

David E. Kandzari, MD, Atlanta, USA

View Study
Orsiro Mission Lower TV-MI
PRINCIPAL INVESTIGATOR OF THE FDA PIVOTAL BIOFLOW-V TRIAL PRESENTS 5-YEAR OUTCOMES2

David E. Kandzari, MD, Atlanta, USA

View Study

TLF – Target Lesion Failure; TV-MI - Target Vessel Myocardial Infarction; ST – Stent Thrombosis2

a Based on statistically significant lower TV-MI and late/very late definite/probable ST rates through 5 years for Orsiro vs Xience in the BIOFLOW-V trial; b In comparison to Xience, based on BIOFLOW-V 5-year results.

1. BIOTRONIK data on file, status January 2020; 2. Kandzari D Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents for Coronary Revascularization: Final 5-year Outcomes from the Randomized BIOFLOW V Trial. Presented at CRT 2022. Presented information is based on unrounded values.

Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies.
Xience is a trademark or registered trademark of the Abbott Group of Companies. 

© 2022 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.